XBiotech Inc. reported a net loss of $6.7 million for the second quarter of 2026, compared to a loss of $1.8 million in the same period of the previous year. For the first half of 2026, the company recorded a net loss of $12.2 million, slightly down from $12.6 million in the first half of 2025. The company's total operating expenses for the second quarter were $6.1 million, a decrease from $6.3 million year-over-year. Research and development expenses accounted for the majority of these costs, totaling $5.3 million for the quarter, which is consistent with the previous year, while general and administrative expenses decreased to $0.9 million from $1.0 million.
In terms of financial position, XBiotech's cash and cash equivalents stood at $109.5 million as of June 30, 2026, down from $152.9 million a year earlier. The decrease in cash is attributed to ongoing operational losses and a significant payment related to a bonus for the former CEO. The company’s total assets decreased to $133.7 million from $150.1 million at the end of 2025, primarily due to a reduction in cash and cash equivalents. Shareholders' equity also declined to $128.5 million from $140.4 million, reflecting the accumulated deficit which increased to $148.6 million.
Operationally, XBiotech has maintained a workforce of 87 employees as of June 30, 2026, although a workforce reduction was implemented shortly after this date. The company continues to focus on its clinical development pipeline, which includes a Phase II clinical trial for a new IL-1a targeting antibody aimed at treating active axial spondyloarthritis. The company has not generated any revenue in 2026 and does not expect to do so until its drug candidates receive regulatory approval and are commercialized.
Looking ahead, XBiotech anticipates continued operating losses as it advances its drug candidates through clinical testing. The company has indicated that it will need to generate significant revenues to achieve profitability, which may not occur in the foreseeable future. Management has expressed confidence that the current cash reserves will support the company through key clinical milestones over the next 12 months, despite the challenges posed by increasing research and development costs and general inflationary pressures.
About XBiotech Inc.
XBiotech Inc. is a biopharmaceutical company specializing in discovering and developing True Human monoclonal antibodies from naturally immune donors. Its focus includes therapies targeting inflammatory and infectious diseases, notably IL-1a inhibitors for conditions like cancer, arthritis, and stroke. The company leverages proprietary manufacturing and clinical infrastructure, aiming to deliver safer, more effective biologics with potential for targeted, differentiated treatments across multiple medical indications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov